Patents Assigned to Takeda Pharmaceuticals Company Limited
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20220081399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
    Patent number: 11273182
    Abstract: Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 15, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Eduardo Bravo, Maria Pascual
  • Heterocyclic compound
    Patent number: 11274101
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 15, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • ANTI-FACTOR IX PADUA ANTIBODIES
    Publication number: 20220056150
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk VOELKEL, Robert PACHLINGER, Hanspeter ROTTENSTEINER, Alfred WEBER, Andrea ENGELMAIER
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20220056028
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • ADAMTS13 protein cell culture supernatant
    Patent number: 11254921
    Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 11254731
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE
    Publication number: 20220050107
    Abstract: The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.
    Type: Application
    Filed: December 12, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Laura EDGINGTON-MITCHELL, Bethany M. ANDERSON, Daniel P. POOLE, Luigi AURELIO, Paulina KASPERKIEWICZ, Marcin DRAG, Nigel BUNNETT
  • USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20220047688
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Bruce EWENSTEIN, Brahm GOLDSTEIN, Bernhard MAJER, Paolo ROSSATO, Friedrich SCHEIFLINGER, Marietta TURECEK
  • HETEROCYCLIC COMPOUND
    Publication number: 20220048916
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • CONDENSED-CYCLIC COMPOUND
    Publication number: 20220041581
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: February 10, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu SASAKI, Yasutomi ASANO, Hironobu MAEZAKI, Ayumu SATO, Kazuaki TAKAMI, Masaki SETO, Haruhi ANDO, Shuji KITAMURA, Steve L. SWANN
  • Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
    Patent number: 11242380
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Heterocyclic compound
    Patent number: 11242348
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA
    Publication number: 20220033521
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Application
    Filed: June 11, 2021
    Publication date: February 3, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Heterocyclic compound
    Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • DRUG DELIVERY SYSTEM USING SOLUTION
    Publication number: 20220023207
    Abstract: The present invention provides a means excellent in efficiency of introduction of a nucleic acid, a protein, a complex thereof, or the like into cells, in particular a method using a solution for transduction.
    Type: Application
    Filed: November 29, 2019
    Publication date: January 27, 2022
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Akitsu HOTTA, Naoko ISHIHARA, Ryuichi NISHIGAKI, Masaki SETO
  • Heterocyclic compound
    Patent number: 11230545
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • Heterocyclic compound
    Patent number: 11230541
    Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: January 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Eiji Kimura, Masaki Ogino, Yasuhisa Kohara, Tomoko Ohashi, Tomohiro Kaku, Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017530
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017514
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Yoshito TERAO, Masanori KAWASAKI